Sirna Reports 70-percent drop in Q3 Revenues
Sirna Therapeutics reported last week its financial results for the third quarter 2004, posting a sharp drop off in revenues amid a decline in expenses.
Sirna’s revenues for the third quarter were $84,000, compared with $283,000 in the year-ago period. The company attributed the 70 percent decline to the completion of ribozyme-related manufacturing programs as its new aptamer manufacturing arrangement with Archemix gets underway.